We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Automated HSV1 and 2 Test Receives US Marketing Approval

By LabMedica International staff writers
Posted on 14 Jun 2015
An automated real-time polymerase chain reaction (PCR) assay for the direct detection and differentiation of HSV1 (herpes simplex virus 1) and HSV2 (herpes simplex virus 2) DNA in anogenital specimens from symptomatic patients has been certified for diagnostic use in the United States.

The [US] Food and Drug Administration (FDA) has issued 510(k) clearance, which allows marketing as a diagnostic tool, for the Roche (Basel, Switzerland) cobas HSV1 and 2 Test for the early, simultaneous detection of HSV1 and HSV2 DNA in anogenital specimens.

The Roche HSV assay was developed for use on the cobas 4800 system. More...
This system was designed to automatically perform real-time PCR for medium- to high-throughput laboratories (up to 384 samples a day). The system incorporates fully automated sample preparation from primary vials with ready-to-use, load-and-go reagents. No thawing or mixing is required and a full run of 94 samples can be set up in less than 20 minutes.

The cobas HSV1 and 2 Test joins the expanding US system menu that currently includes the cobas CT/NG Test (chlamydia/gonorrhea), cobas HPV Test, cobas BRAF V600 Mutation Test, the cobas EGFR Mutation Test, and the cobas MRSA/SA Test.

"The addition of the cobas HSV 1 and 2 Test expands the menu for the cobas 4800 System, enabling labs to experience increased efficiency with innovative testing solutions," said Paul Brown, head of Roche Molecular Diagnostics. "This highly sensitive and specific new test for the detection of herpes simplex virus delivers reliable results to physicians for optimal patient treatment and clinical management decisions."

Related Links:

Roche



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.